Holen Sie sich die Stockscreener-App
25.96
0.80%
-0.21
Vorhandelsmarkt:
26.01
0.05
+0.19%
Dyne Therapeutics Inc Aktie (DYN) Neueste Nachrichten
Dyne Therapeutics, Inc. SEC Filing (Aug 13, 2026) - Stock Titan
DYN Company (Nasdaq: DYN) holder plans 4,986-share sale worth $131,034 - Stock Titan
DYN (DYN) insider notice details planned share sale and prior trades - Stock Titan
DYN (DYN) shareholder Doug Kerr plans sale of 2,443 common shares - Stock Titan
Dyne Therapeutics (DYN): Atlas Venture funds report 3.6% beneficial stake in 13G/A - Stock Titan
Dyne Therapeutics (DYN) gains 7.3% institutional holder Janus Henderson - Stock Titan
Dyne Therapeutics stock hits 52-week high at 27.19 USD By Investing.com - Investing.com Australia
Dyne Therapeutics stock hits 52-week high at 27.19 USD - Investing.com
Biotech Stocks At 52-Week HighsALMR +30% On Q2 Reports, DYN, CGEM, DXCM, CAH - RTTNews
FMR LLC Expands Dyne Therapeutics Stake: A Strategic Bet on Neur - GuruFocus
DYN Stock Gains As It Gears Up For Accelerated Approval Of DMD Therapy: Wall Street Sees 140% Upside - Stocktwits
Dyne Therapeutics (NASDAQ:DYN) Hits New 52-Week HighHere's What Happened - MarketBeat
The Bull Case For Dyne Therapeutics (DYN) Could Change Following FDA Clearance Of DYNE-302 Trial - simplywall.st
Discipline and Rules-Based Execution in DYN Response - Stock Traders Daily
Dyne Therapeutics (DYN) Gets FDA Clearance With Valuation Questions Back In Focus - Sahm
Dimensional Fund Advisors LP Has $17.24 Million Holdings in Dyne Therapeutics, Inc. $DYN - MarketBeat
Dyne Therapeutics Inc (DYN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Dyne Therapeutics, Inc. Revenue Breakdown – NASDAQ:DYN - TradingView
FMR LLC (DYN) discloses 6.8% Dyne Therapeutics stake in amended ownership filing - Stock Titan
Dyne Therapeutics stock hits 52-week high at 26.8 USD By Investing.com - Investing.com UK
Dyne Therapeutics stock hits 52-week high at 26.8 USD - Investing.com
Dyne Therapeutics (NASDAQ:DYN) Reaches New 52-Week HighShould You Buy? - MarketBeat
Analysts Offer Insights on Healthcare Companies: Dyne Therapeutics (DYN) and Crescent Biopharma (CBIO) - The Globe and Mail
Dyne Therapeutics, Inc. (DYN) Stock Analysis: Exploring a 56% Potential Upside for Biotech Investors - DirectorsTalk Interviews
Weekly Recap: BLA accepted for Z‑Rostudirsen and RBC raises PT to $35 - TradingView
Dyne Therapeutics, Inc. $DYN Shares Purchased by Renaissance Technologies LLC - MarketBeat
Dyne Therapeutics, Inc. $DYN Shares Purchased by Perceptive Advisors LLC - MarketBeat
DYNE THERAPEUTICS, INC : RBC RAISES TARGET PRICE TO $35 FROM $30 - webull.com
Morgan Stanley Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Cuts Target Price to $45 - Moomoo
A Quick Look at Today's Ratings for Dyne Therapeutics(DYN.US), With a Forecast Between $44 to $47 - Moomoo
Dyne Therapeutics, Inc. $DYN Shares Sold by Vivo Capital LLC - MarketBeat
RBC Raises Price Target on Dyne Therapeutics to $35 From $30, Keeps Outperform, Speculative Risk - marketscreener.com
Analysts Offer Insights on Healthcare Companies: Biogen (BIIB) and Dyne Therapeutics (DYN) - The Globe and Mail
DYN SWOT Analysis: Financial Challenges and Growth Potential Rev - GuruFocus
Dyne Therapeutics reports Q2 net loss $178.6M, cash $898.5M; BLA for z-rostudirsen accepted with PDUFA Jan 21, 2027 - TradingView
Dyne Therapeutics Net Loss Widens to $178.6 Million in Q2 2026 - quiverquant.com
Dyne Therapeutics Announces U.S. FDA Clearance of Investigational New Drug Application for DYNE-302 in Facioscapulohumeral Muscular Dystrophy - Investing News Network
Dyne Therapeutics receives FDA clearance for FSHD trial - Investing.com
Dyne Therapeutics Announces U.S. FDA Clearance of Investigational New Drug (IND) Application ... - Caledonian Record
Dyne Therapeutics Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for DYNE-302 in Facioscapulohumeral Muscular Dystrophy (FSHD) - marketscreener.com
Dyne Therapeutics Announces U.S. FDA Clearance of - GlobeNewswire
Dyne Therapeutics Inc (DYN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
BlackRock (DYN holder) discloses 11.49M Dyne Therapeutics shares, a 7% stake - Stock Titan
Dyne Therapeutics stock hits 52-week high at 25.06 USD By Investing.com - Investing.com UK
ForDyne B.V. (DYN) files Rule 144 to potentially sell 261,460 common shares - Stock Titan
Dyne Therapeutics stock hits 52-week high at 25.06 USD - Investing.com
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Dyne Therapeutics Inc (DYN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Dyne Therapeutics Inc (DYN) Institutional Confidence - TradingKey
Dyne Therapeutics Inc (DYN) Cash Flow - TradingKey
Dyne Therapeutics Inc (DYN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Dyne Therapeutics Inc (DYN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Dyne Therapeutics Inc (DYN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Dyne Therapeutics Inc (DYN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Why DYN Shares Are Down 10% After-Hours? Day After An FDA Win, Another Announcement Rocks Stock - Stocktwits
Dyne Therapeutics Announces Pricing Of Upsized $375 Million Public Offering - Pulse 2.0
TradingKey - TradingKey
Skorney: FDA's Sarepta Precedent Makes Dyne DMD Approval 'Impossible' to Deny - finance.biggo.com
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Dyne Therapeutics Grants New Hires Options on Up to 358,600 Shares - Stock Titan
Dyne Therapeutics, Inc. $DYN Shares Sold by Siren L.L.C. - MarketBeat
Dyne Therapeutics closes $431.4 million stock offering By Investing.com - Investing.com Nigeria
DYN Initiated Coverage On by Cantor Fitzgerald -- Rating Set to Overweight - GuruFocus
Dyne Therapeutics Upsized Equity Offering Strengthens Cash Runway - The Globe and Mail
Dyne Therapeutics closes $431.4 million stock offering - Investing.com
0.03%
0.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):